Sun Pharmaceutical Agrees To Settle Out Of Court with Novartis over Exelon (India)
This article was originally published in PharmAsia News
Executive Summary
Sun Pharmaceutical Industries agreed to an out-of-court settlement with Novartis over the Indian drug maker's efforts to market a generic of the Novartis drug Exelon (rivastigmine tartrate) for treating Alzheimer's disease. In doing so, Sun joins several other major Indian generics makers in agreeing to an out-of-court settlement with Novartis over Exelon. Sun won U.S. FDA fast-paced approval as the first generic to file, but it and Ranbaxy Laboratories and Dr. Reddy's, as well as U.S.-based Watson Pharmaceuticals, challenged the Novartis patent for Exelon and since reached settlements. Most of the settlements have allowed the generics to market their versions if the innovator gets a share. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 26 March
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 26 March
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
FDA Delivers OTC Monograph Facility Fees For Fiscal 2024 With Highlights On Some RSVPs
FDA “is highlighting” in its FY2024 facility fees announcement, and using italics for “emphasis added” for some statements, that businesses previously but no longer making hand sanitizers, though still selling the products, should contact the agency to assure they’re not assessed fees.